PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: HIV
TB Alliance Trumpets New, Improved Drugs at World Health Assembly
Like polio and leprosy, developed countries have long since tamed tuberculosis. But even now, other parts of the world continue to struggle against the disease, with nearly all (98 percent) of TB’s 1.7 million worldwide deaths occurring in developing countries. TB’s high comorbidity with HIV infections has recently added another level of urgency to efforts [...]
Posted in Corporate Responsibility, Emerging Markets, Global, R&D Also tagged AIDS, Developing country, funding, Médicins Sans Frontières, neglected diseases, TB, TB Alliance, Tuberculosis, WHA, World Health Assembly Leave a comment
Gilead Making a Bundle
Gilead Sciences has once again proven that independent biotechs can innovate with the best of Big Pharma. The Silicon Valley company’s wizardry at weaving multiple drugs into a single weft enabled it to overthrow GlaxoSmithKline as king of HIV in 2007. Yesterday, at the 16th annual Congress of Retroviruses and Opportunistic Infections (CROI), the biotech [...]
Posted in Biotech, Emerging Markets, R&D Also tagged Biotech, Bristol Myers Squibb, Gilead Leave a comment
Clinton Tinkers With Malaria Market
A team of reporters and camera crews packed into the headquarters of the Clinton Foundation on West 125th Street this afternoon to hear the details of former President Bill Clinton’s plan to tinker with the market for malaria drugs “in a way that has positive implications for the pharmaceutical companies,” he said.
Posted in Corporate Responsibility Also tagged ACT, Africa, AIDS, artemisinin, Bill Clinton, Clinton Foundation, R&D 4 Comments
HIV Market Banking on Fixed-Dose Treatments